Onco Actu du 1er août 2016

	1. Biologie
Halting Translation of Cancer-Promoting Proteins [GEN] Essentially, the study points to a secret lever that triggers translation of a special subset of mRNAs—perhaps only 500 out of some 10,000 mRNAs produced by a cell. The study adds a new wrinkle to a familiar insight, one that emerged more than 40 years ago, that a so-called initiation protein must bind to a chemical handle on the end of each mRNA to start it through the protein manufacturing plant, the ribosome.
	2. Etiologie
Ovarian cancer risk nearly doubles in women who douche [Reuters] Prior studies have linked douching, or vaginal washing with a device, to yeast infections, pelvic inflammatory disease and ectopic pregnancies. Researchers have also found associations between douching and cervical cancer, reduced fertility, HIV and other sexually transmitted diseases. But the new National Institute of Environmental Health Sciences study is the first to tie cancer of the ovaries to the procedure routinely practiced by millions of American women.
	5.12 Immunothérapies
Harnessing the Immune System to Fight Cancer [NY Times] New drugs and methods of altering a patient’s own immune cells are helping some cancer patients — but not all — even when standard treatments fail.
	5.2.3 Pharma - économie
Merck Needs Stronger Top-Line Medicine [Bloomberg] Merck's cancer drug Keytruda has been absolutely dominated by Bristol-Myers Squibb's own entry, Opdivo. Merck's drug requires doctors test patients to identify suitable candidates. Bristol's drug can be prescribed without that step and reaches more patients, giving it a major advantage.
	5.3 Traitements - FDA, EMA,...
Modelling and simulation in the development and regulatory review of medicines [EMA] Using specialised software platforms, these models aim to simulate the concentration of a medicine in the body over time. They are increasingly used by medicine developers for various purposes such as predicting the interaction between medicines in the body or helping to define the initial dose of a medicine in paediatric and first-in-human trials.
	5.4 Traitements - Economie
Wales endorses NHS use of Celgene’s Revlimid [PharmaTimes] The All Wales Medicines Strategy Group (AWMSG) is supporting use of Revlimid (lenalidomide) in newly diagnosed multiple myeloma patients who are not eligible for transplant and are unsuitable for thalidomide-containing regimens.
	6. Lutte contre les cancers
American Society of Breast Surgeons Consensus Panel Recommends Against Routine Use of Contralateral Prophylactic Mastectomy [ACBS] New Position Paper Encourages Physician-Patient Discussion about Risks and Benefits.
	6.10 Politiques
The road to REF 2021: why I welcome Lord Stern’s blueprint for research assessment [The Guardian] The Stern Review has the potential to create a more diverse, patient and outward-facing research culture in Britain’s universities
	6.10.1 Politiques (USA)
Why Democratic convention viewers saw so many drug ads [STAT] Democratic politicians made a few jabs at the pharmaceutical industry at their convention this week, but viewers tuning in at home saw something of a counterargument during commercial breaks: a stream of ads promoting drugs — and the drug industry.
	6.4 Médico-éco
NHS under pressure from increase in cancer survivors, report warns [The Guardian] Around 625,000 people in the UK are estimated to be facing poor health or disability after treatment for cancer. Long-term consequences can range from painful lower-leg swelling in women following breast cancer to emotional trauma, and with the number of people living with cancer in the UK set to grow from 2.5 million to 4 million by 2030, more people will need support.
	6.7 DMP, Big Data & applis
A Ransomware Epidemic And An Overdue National Health IT Safety Center [Health Affairs] We are at crossroads. We could continue to obfuscate and ignore obvious safety issues, including being easy targets for cyber-criminals, or we could work together to understand safety events, learn from them, identify best practices to prevent them, and work on building a safe and effective health IT infrastructure for our country.